New Orleans American Queen

Over the last decade we have heard much about cyclin dependent kinase inhibition from numerous clinical trials in metastatic and adjuvant breast cancer on various CDK4/6 inhibitors, and to a lesser extent CDK7 and CDK9.

It’s a large family, so what about other targets within the family?

In our latest article from the annual meeting of the American Association for Cancer Research, we take a look at another such target – CDK12 – in the first of a two-part mini series…

BSB subscribers can read our latest conference coverage from AACR plus commentary and analysis – you can either log-in or click to access.

This content is restricted to subscribers

Posted by